24-Apr-2026
No headlines found.
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
Business Wire (Thu, 16-Apr 4:05 PM ET)
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
Business Wire (Tue, 14-Apr 4:05 PM ET)
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
Business Wire (Fri, 20-Mar 7:30 AM ET)
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
Business Wire (Thu, 19-Mar 4:05 PM ET)
Business Wire (Tue, 10-Mar 5:05 PM ET)
Business Wire (Thu, 19-Feb 8:00 AM ET)
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
Business Wire (Wed, 4-Feb 4:05 PM ET)
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
Business Wire (Tue, 3-Feb 4:05 PM ET)
QIAGEN Appoints Mark Stevenson to Supervisory Board
Business Wire (Mon, 26-Jan 4:05 PM ET)
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of April 24, 2026, QGEN stock price climbed to $38.41 with 1,046,273 million shares trading.
QGEN has a beta of 0.84, meaning it tends to be less sensitive to market movements. QGEN has a correlation of 0.10 to the broad based SPY ETF.
QGEN has a market cap of $7.91 billion. This is considered a Mid Cap stock.
Last quarter Qiagen N.V. Common Shares reported $540 million in Revenue and $.62 earnings per share. This beat revenue expectation by $12 million and met earnings estimates .
In the last 3 years, QGEN traded as high as $57.82 and as low as $36.84.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, FXH, IWS, PBE.
QGEN has underperformed the market in the last year with a price return of -4.9% while the SPY ETF gained +31.9%. QGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.9% and -6.1%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
QGEN support price is $37.27 and resistance is $38.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN shares will trade within this expected range on the day.